Biogen
1D
1W
1M
3M
1Y
5Y
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis.
CEOChristopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees9,610
Employees9,610
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded1978
Founded1978
Employees9,610
Employees9,610
BIIB Key Statistics
Market cap42.02B
Market cap42.02B
Price-Earnings ratio14.89
Price-Earnings ratio14.89
Dividend yield—
Dividend yield—
Average volume1.02M
Average volume1.02M
High today$293.01
High today$293.01
Low today$289.67
Low today$289.67
Open price$292.34
Open price$292.34
Volume557.32K
Volume557.32K
52 Week high$311.88
52 Week high$311.88
52 Week low$187.16
52 Week low$187.16
BIIB News
Reuters 2h
UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen(Adds background) Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketi...
Yahoo Finance 3h
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European ... - Yahoo FinanceBiogen Inc. TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nas...
Reuters 6d
Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - ReutersJan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the marke...
Analyst ratings
64%
of 33 ratingsBuy
63.6%
Hold
36.4%
Sell
0%
BIIB Earnings
$0.00
$1.89
$3.79
$5.68
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Estimated$3.48 per share
Estimated$3.48 per share
ActualAvailable Feb 15, Pre-Market
ActualAvailable Feb 15, Pre-Market
More BIIB News
Investor's Business Daily 6d
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's DrugEli Lilly (LLY) stock dipped Friday after the Food and Drug Administration unexpectedly rejected its request for an accelerated approval of its Alzheimer's trea...